Workflow
Systemic treatment for vitiligo
icon
Search documents
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo
Prnewswire· 2026-02-03 13:00
Vitiligo is a chronic, autoimmune disease that imposes a significant psychosocial burden, profoundly affecting an individual's confidence, identity and daily life. NSV, the most common form of vitiligo (afflicting approximately 84% of patients), is marked by symmetrical and bilateral depigmented white patches and is prone to unpredictable progression even after long periods of stability. Vitiligo management is anchored in three primary treatment goals: disease stabilization, re-pigmentation, and maintaining ...